VBIV / VBI Vaccines to focus on hep B treatments, conduct 1-for-30 reverse stock split

VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protec more_horizontal

VBI Vaccines (NASDAQ: VBIV ) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. VBI Vaccines announ more_horizontal

VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to l more_horizontal

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-3 more_horizontal

VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut opera more_horizontal

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the nu more_horizontal

Healthcare has become a bona fide stock picker's market this year. more_horizontal

Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared f more_horizontal